Stockscreener 앱 받기
429.53
1.43%
-6.25
시간 외 거래:
429.18
-0.35
-0.08%
전일 마감가:
$435.78
열려 있는:
$430.14
하루 거래량:
256.31K
Relative Volume:
0.73
시가총액:
$9.54B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-17.10
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
-0.11%
1개월 성능:
+1.25%
6개월 성능:
+29.65%
1년 성능:
+97.94%
1일 변동 폭
$426.65
$435.00
1주일 범위
$413.82
$436.84
52주 변동 폭
$213.71
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
429.53 | 9.71B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Madrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025 - The Manila Times
Madrigal (NASDAQ: MDGL) to present cirrhosis and real-world Rezdiffra data at AASLD 2025 - Stock Titan
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsBond Market & Capital Efficiency Focused Ideas - newser.com
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Value Report & Consistent Income Trade Recommendations - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 Sector Moves & Stock Portfolio Risk Management - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthMarket Performance Report & Expert Approved Momentum Trade Ideas - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.Quarterly Investment Review & Precise Buy Zone Identification - newser.com
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthTrade Signal Summary & Expert Approved Momentum Ideas - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis toolsMarket Risk Summary & Reliable Intraday Trade Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock profit from AI boom2025 Earnings Impact & Daily Chart Pattern Signals - Fundação Cultural do Pará
Madrigal Pharmaceuticals Inc. stock chart pattern explainedQuarterly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Is it too late to sell Madrigal Pharmaceuticals Inc.Quarterly Risk Review & Low Drawdown Trading Strategies - newser.com
Madrigal Pharmaceuticals set to unveil Q3 2025 financial results on November 4 - Traders Union
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.July 2025 Review & Daily Technical Forecast Reports - newser.com
Is Madrigal Pharmaceuticals Inc a good long term investmentProtective Put Strategies & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Madrigal Pharmaceuticals: Rezdiffra Commercialization Bode Well For Continued Growth MDGL - Seeking Alpha
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.47%
0.34%
자본화:
|
볼륨(24시간):